32,833 Shares in Diplomat Pharmacy, Inc. (DPLO) Purchased by PEAK6 Investments L.P.

PEAK6 Investments L.P. purchased a new position in shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 32,833 shares of the company’s stock, valued at approximately $680,000.

A number of other large investors have also modified their holdings of DPLO. Royal Bank of Canada boosted its holdings in Diplomat Pharmacy by 25.0% in the second quarter. Royal Bank of Canada now owns 35,266 shares of the company’s stock valued at $521,000 after purchasing an additional 7,056 shares in the last quarter. State of Wisconsin Investment Board boosted its holdings in Diplomat Pharmacy by 9.9% in the second quarter. State of Wisconsin Investment Board now owns 278,000 shares of the company’s stock valued at $4,114,000 after purchasing an additional 25,000 shares in the last quarter. Cortina Asset Management LLC boosted its holdings in Diplomat Pharmacy by 538.8% in the third quarter. Cortina Asset Management LLC now owns 1,616,792 shares of the company’s stock valued at $33,484,000 after purchasing an additional 1,363,696 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in Diplomat Pharmacy by 19.3% in the second quarter. Ameriprise Financial Inc. now owns 272,979 shares of the company’s stock valued at $4,043,000 after purchasing an additional 44,135 shares in the last quarter. Finally, Crossmark Global Holdings Inc. acquired a new stake in shares of Diplomat Pharmacy in the third quarter valued at approximately $538,000. Institutional investors own 72.48% of the company’s stock.

Diplomat Pharmacy, Inc. (NYSE DPLO) opened at $18.45 on Friday. Diplomat Pharmacy, Inc. has a 52-week low of $12.25 and a 52-week high of $21.99. The firm has a market capitalization of $1,270.00, a price-to-earnings ratio of 23.74, a PEG ratio of 3.30 and a beta of 0.61. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.34 and a quick ratio of 0.82.

Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings results on Monday, November 6th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same quarter last year, the business posted $0.21 earnings per share. The business’s revenue for the quarter was down 4.8% on a year-over-year basis. sell-side analysts forecast that Diplomat Pharmacy, Inc. will post 0.85 EPS for the current year.

In other Diplomat Pharmacy news, Director Jeffrey G. Park purchased 3,000 shares of the firm’s stock in a transaction on Monday, November 20th. The shares were purchased at an average cost of $15.46 per share, with a total value of $46,380.00. Following the purchase, the director now owns 7,640 shares in the company, valued at $118,114.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, President Joel Saban purchased 10,000 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was acquired at an average cost of $15.24 per share, for a total transaction of $152,400.00. Following the completion of the purchase, the president now owns 12,000 shares in the company, valued at approximately $182,880. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 15,000 shares of company stock valued at $228,780. Company insiders own 30.20% of the company’s stock.

Several equities research analysts recently weighed in on DPLO shares. Robert W. Baird downgraded Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $24.00 to $18.00 in a report on Thursday, November 16th. BidaskClub downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. Mizuho increased their price target on Diplomat Pharmacy from $16.00 to $20.00 and gave the stock a “neutral” rating in a report on Tuesday, November 7th. Leerink Swann increased their price target on Diplomat Pharmacy from $16.00 to $20.00 and gave the stock a “market perform” rating in a report on Tuesday, November 7th. Finally, Needham & Company LLC increased their price target on Diplomat Pharmacy from $23.75 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. Six investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $20.39.

COPYRIGHT VIOLATION WARNING: “32,833 Shares in Diplomat Pharmacy, Inc. (DPLO) Purchased by PEAK6 Investments L.P.” was reported by Week Herald and is the property of of Week Herald. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://weekherald.com/2017/12/08/32833-shares-in-diplomat-pharmacy-inc-dplo-purchased-by-peak6-investments-l-p.html.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply